A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

OBJECTIVE: A randomized, placebo-controlled, double-blind, multicenter 52-week phase 2 trial of resveratrol in individuals with mild to moderate Alzheimer disease (AD) examined its safety and tolerability and effects on biomarker (plasma Aβ40 and Aβ42, CSF Aβ40, Aβ42, tau, and phospho-tau 181) and v...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neurology
Egile Nagusiak: Turner, R. Scott, Thomas, Ronald G., Craft, Suzanne, van Dyck, Christopher H., Mintzer, Jacobo, Reynolds, Brigid A., Brewer, James B., Rissman, Robert A., Raman, Rema, Aisen, Paul S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Lippincott Williams & Wilkins 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4626244/
https://ncbi.nlm.nih.gov/pubmed/26362286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000002035
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak